Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

CHICAGO--(BUSINESS WIRE)--Jun 7, 2007 - Clinical results from a Phase II study presented for the first time at the American Headache Society (AHS) annual meeting showed that MK-0974, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved migraine pain relief two hours after dosing compared to placebo, and the relief was sustained through 24 hours. MK-0974 was generally well tolerated in the study. Responses specific to other measures, such as migraine-associated symptoms, functional disability and use of additional rescue medications also were reported. MK-0974 is Merck's investigational medicine in Phase III clinical development for the acute treatment of migraine in adults and, if approved, may be the first in a new class of migraine treatments since the approval of the first triptan drug in 1991.

"The findings of this early-stage trial demonstrate the therapeutic potential of MK-0974 for the acute treatment of migraines," said Tony Ho, M.D., senior director of Clinical Neuroscience, Merck Research Laboratories. "Larger clinical trials, such as those now underway, will provide more insight into the efficacy and safety profile of MK-0974."

About MK-0974

MK-0974 is an antagonist of the receptor for CGRP, a primary neuropeptide involved in the pathophysiology of migraine. CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the transmission of migraine pain. During migraine attacks, CGRP activates these receptors and facilitates the transmission of pain impulses. MK-0974 blocks the binding of CGRP to receptors within these areas and thereby is believed to inhibit the transmission of pain signals that lead to migraine headaches.

Study design

The findings being presented are from a randomized, double-blind, placebo- and active-controlled dose-ranging clinical trial in patients wi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:7/3/2009)... Texas, July 3 In groun...f North Texas Health Science Center at Fort Wort...tion can protect the brain following brain injury....ma patients in North Texas. , , James Simpkin... Department of Pharmacology and Neuroscience, and ...
(Date:7/3/2009)...Finland, July 3 BioCis Pharma Ltd....its headquarters in Turku, Finland,announced pos... ProtoCure(TM),emulsion cream, the company,s nove..., placebo-controlled study, conducted in Finland, ... dermatitis who applied the ProtoCure,emulsion cr...
(Date:7/2/2009)... Belgium and LUND, Sweden, July 3 /PRNewswire-Firs...R) and co-development partner,BioInvent Internati...,recruitment of a second cohort of patients for th...tion of recruitment of the first cohort of 100,pa...acting anticoagulant that,is being developed for ...
(Date:7/2/2009)...ll. and BRISTOL, Tenn., July 2 /PRNewswire-FirstCa... ) and King Pharmaceuticals, Inc. (NYSE: KG ) an...ration (FDA) has issued a Complete Response Letter...ox (oxycodone HC1, USP and niacin, USP) Tablets CI...elief of moderate-to-severe pain. , , (Logo: ...
Breaking Medicine Technology:UNT Health Science Center's Groundbreaking Research Applied to Protecting Brain After Traumatic Injury 2UNT Health Science Center's Groundbreaking Research Applied to Protecting Brain After Traumatic Injury 3BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 2ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 2ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 3ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 4ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 5Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 2Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 3BMP Sunstone to Present at the 20th Annual Piper Jaffray Health Care Conference 9420 1Imaging in Living Color with Siemens Molecular CT 9419 1Imaging in Living Color with Siemens Molecular CT 9419 2Imaging in Living Color with Siemens Molecular CT 9419 3Imaging in Living Color with Siemens Molecular CT 9419 4IDO2 an active enzyme to target in pancreatic cancer 30873 1IDO2 an active enzyme to target in pancreatic cancer 30873 2News from the December 2008 Journal of the American Dietetic Association 6099 1News from the December 2008 Journal of the American Dietetic Association 6099 2
... Hypertension,Treatment Valsartan in Preventing Ca...pril 26, 2007 /Xinhua-PRNewswire/ -- The clinical,... clinical trial,headed by the Jikei University Sch...ationally renowned medical journal The,Lancet. The... of,the largest cardiovascular intervention trials...
...,Merck Serono S.A. (virt-x: SEO) and its partner N... today that Professor,Fabrizio Stocchi, MD, PhD, w...al of safinamide as an adjunctive treatment to,dop...ease (PD),patients at the American Academy of Neur...m 28 April to 5 May 2007. , The abstract entitled ...
Other Medicine Technology:First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 2First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 3First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 4Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 2Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 3Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 4
(Date:7/4/2009)..., WASHINGTON, July 4 ...ay the official opening of a new 50 bed Critical C...1310 Southern Ave, in SE Washington. The new hospi... United Medical Center will ultimately provide car...n, as well as provide upward of 400 new jobs to th...
(Date:7/4/2009)...Education, income and health care may explain resu...althDay News) -- Older people in the United States...on a memory and awareness test, possibly because o...n and the fact that American adults receive more a... suggests. , The test assessed immediate and de...
(Date:7/4/2009)...Taking simple precautions can help prevent pain a...y 4 (HealthDay News) -- While baby boomers are not...important as ever, but certain precautions are in ..., they should take extra steps to protect themselv...a spokesman for the American Academy of Orthopaedi...
(Date:7/4/2009)...Even when budgets are tight, experts say, health a...Y, July 4 (HealthDay News) -- Most people are cutt...save more and make do with less. But can you cut b... out, experts say you can -- if you,re smart about... still eating healthily, staying physically fit an...
Breaking Medicine News(10 mins):Health News:Specialty Hospitals of America Accepts First Patients in New Long Term Critical Care Hospital Located in South East Washington 2Health News:On Memory, Older Americans Outsmart the English 2Health News:Exercise Tips to Keep Boomers on Their Feet 2Health News:Living Healthily on Less 2Health News:Living Healthily on Less 3Health News:Living Healthily on Less 4
...od and Drug Administration has avowed Biolase Tech... vend its Waterlase laser therapy for root canal p...s the first by the FDA for a laser root canal and ...as well as shaping of the root canal. The Waterlas...
... is on the way for longtime sufferers. New researc...ntidepressants and stress-management training can ...of chronic tension headches, which strike millions...th mild to moderate head pain that occurs more tha...
...chers from the university of Michigan state that W... percent more likely than nonsmokers to give birth...of the birth defect rises with the number of cigar...fter factors like the mother's race, age and educa...
...ch says that giving extra radiotherapy to patients...e risk of cancer recurring in the breast. //The re...be changed immediately, particularly for younger w...ook part in the study. The majority of patients ha...
Other Medicine News:
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: